Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Impact of cardiopulmonary bypass on platelet lipids and bleeding after cardiac surgery

Official title: Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.

Run by Université Catholique de Louvain · NCT07630987 · Data updated 2026-11-12

This study tests how CPB changes platelet lipid metabolism and procoagulant platelets to see if these changes relate to inflammation and bleeding after cardiac surgery.

More Cardiac Surgery trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversité Catholique de Louvain
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Brussels)
StatusRecruiting
StartedApril 15, 2026
Main results expectedJanuary 2029
Study endsJanuary 2030
Registry record updatedNovember 6, 2026
Trial IDNCT07630987 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with coronary disease and/or severe valvular disease undergoing elective cardiac surgery with CPB.

Probably not a fit

Patients without CPB exposure or those not experiencing CPB-related platelet alterations may see no direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PLACARD project investigates how cardiopulmonary bypass alters platelet lipid metabolism and the formation of procoagulant platelets in patients undergoing cardiac surgery. Researchers will analyze platelet lipid profiles and bioenergetics before, during, and after surgery and relate these ex vivo findings to postoperative inflammatory markers and bleeding outcomes in the ICU. The study uses arterial blood sampling at multiple time points to characterize the hemostatic and inflammatory milieu associated with CPB. It aims to clarify whether CPB-induced platelet changes contribute to adverse postoperative events and whether these pathways could be targeted to improve outcomes.

Why it matters

Potential benefit: If successful, the study could illuminate mechanisms linking CPB, platelet biology, and postoperative inflammation and bleeding, potentially guiding future therapies to reduce complications.

How similar studies have gone: Prior work suggests platelet lipid metabolism can influence thrombo-inflammatory responses, but the specific CPB-related platelet lipid changes in this context are exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (≥ 18 years old) suffering from coronary disease and/or severe valvular dysfunction (mitral or aortic) undergoing elective coronary angiography or cardiac surgery with cardiopulmonary bypass.

Exclusion Criteria:

* Uninterrupted preoperative dual antiplatelet therapy
* Active chronic inflammatory disease
* Recent chemotherapy or immunotherapy (\< 3 months)
* Active solid malignancy
* History of hematologic malignancy
* Hemophilia or other coagulopathy
* History of thrombocytopenia (\< 100,000 platelets/mm³)
* Recent administration of thrombopoietin receptor agonist or immunoglobulins
* History of thrombopathy, thrombocytosis, or myeloproliferative syndrome
* History of heparin-induced thrombocytopenia (HIT)
* Cirrhosis or hepatic fibrosis (with or without hypersplenism)
* History of splenectomy, regardless of initial indication
* History of systemic autoimmune disease (e.g., systemic lupus erythematosus, scleroderma, antiphospholipid syndrome, systemic vasculitis)
* Recent major surgery (\< 3 months)
* Severe renal insufficiency (eGFR ≤ 30 mL/min/m²) with or without dialysis
* Recent or chronic corticosteroid therapy
* Recent acute coronary syndrome, STEMI type (\< 3 months)
* Urgent surgery or procedure
* Preoperative hemodynamic instability

Where it's running

  • Cliniques universitaires Saint-Luc
    Brussels, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.